[go: up one dir, main page]

MX9700036A - Combination therapy for hiv infection. - Google Patents

Combination therapy for hiv infection.

Info

Publication number
MX9700036A
MX9700036A MX9700036A MX9700036A MX9700036A MX 9700036 A MX9700036 A MX 9700036A MX 9700036 A MX9700036 A MX 9700036A MX 9700036 A MX9700036 A MX 9700036A MX 9700036 A MX9700036 A MX 9700036A
Authority
MX
Mexico
Prior art keywords
hiv infection
treating
hiv
combination therapy
combination
Prior art date
Application number
MX9700036A
Other languages
Spanish (es)
Inventor
Emilio A Emini
Joel R Huff
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MX9700036A publication Critical patent/MX9700036A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La combinacion del compuesto J inhibidor de la proteasa del VIH y a uno más de entre nevarapina o un derivado de la x-APA es util en la inhibicion de la proteasa del VHI, la inhibicion de la transcriptasa inversa de VIH, la prevencion y el tratamiento de la infeccion por el VIH y el tratamiento del SIDA, ya sea como compuestos, sales farmacéuticamente aceptables, ingredientes de composiciones farmacéuticas, ya sea o no en combinacion con otros agentes antivirales, inmunomoduladores, antibioticos o vacunas. Se describen también métodos para tratar el SIDA y métodos para evitar o tratar la infeccion por el VIH.The combination of the HIV protease inhibitor compound J and one of nevarapin or an x-APA derivative is useful in inhibiting HIV protease, inhibiting HIV reverse transcriptase, preventing and treating of HIV infection and AIDS treatment, either as compounds, pharmaceutically acceptable salts, ingredients of pharmaceutical compositions, whether or not in combination with other antiviral agents, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating HIV infection are also described.

MX9700036A 1994-06-27 1995-06-23 Combination therapy for hiv infection. MX9700036A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26708594A 1994-06-27 1994-06-27
PCT/US1995/007690 WO1996000068A2 (en) 1994-06-27 1995-06-23 Combination therapy for hiv infection

Publications (1)

Publication Number Publication Date
MX9700036A true MX9700036A (en) 1997-04-30

Family

ID=23017251

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700036A MX9700036A (en) 1994-06-27 1995-06-23 Combination therapy for hiv infection.

Country Status (14)

Country Link
EP (1) EP0767664A2 (en)
JP (1) JPH10503178A (en)
AU (1) AU2863895A (en)
CA (1) CA2193221A1 (en)
CZ (1) CZ375196A3 (en)
FI (1) FI965196A0 (en)
HU (1) HUT76546A (en)
IL (1) IL114208A0 (en)
MX (1) MX9700036A (en)
NO (1) NO965591D0 (en)
PL (1) PL317876A1 (en)
SK (1) SK163996A3 (en)
WO (1) WO1996000068A2 (en)
ZA (1) ZA955269B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689761B1 (en) 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
EP0872233A1 (en) * 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Antiretroviral compositions with improved bioavailability
GB2324242A (en) * 1997-04-18 1998-10-21 Atindra Nath Chakrabarty Medicaments for treating viral infections
AU775360B2 (en) 1999-09-24 2004-07-29 Janssen Pharmaceutica N.V. Antiviral compositions
JP6936229B2 (en) 2015-09-23 2021-09-15 マルバーン パナリティカル リミテッド Particle characterization

Also Published As

Publication number Publication date
EP0767664A2 (en) 1997-04-16
IL114208A0 (en) 1995-10-31
WO1996000068A2 (en) 1996-01-04
CA2193221A1 (en) 1996-01-04
SK163996A3 (en) 1997-08-06
HUT76546A (en) 1997-09-29
FI965196A7 (en) 1996-12-23
WO1996000068A3 (en) 1996-02-22
FI965196L (en) 1996-12-23
HU9603567D0 (en) 1997-02-28
AU2863895A (en) 1996-01-19
NO965591L (en) 1996-12-27
PL317876A1 (en) 1997-04-28
ZA955269B (en) 1996-02-02
JPH10503178A (en) 1998-03-24
CZ375196A3 (en) 1997-07-16
NO965591D0 (en) 1996-12-27
FI965196A0 (en) 1996-12-23

Similar Documents

Publication Publication Date Title
MX9304775A (en) BENZOXAZINONES AS REVERSE HIV TRANSCRIPTASE INHIBITORS.
ES2125251T3 (en) HIV PROTEASE INHIBITORS.
MX9204720A (en) QUINAZOLINE DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS.
DE60036961D1 (en) GAMMA-HYDROXY-2- (FLUORALKYLAMINOCARBONYL) -1-PIPERAZINE PENTANAMIDE AS AN HIV PROTEASE INHIBITOR
ES2177868T3 (en) HYDROXYETHYLAMINOSULPHONAMIDS OF ALPHA- AND BETA-AMINO ACIDS AS INHIBITORS OF RETROVIRIC PROTEASES.
BR9406503A (en) Combination of compounds, pharmaceutical composition and processes to treat AIDS to prevent and treat HIV infection and to inhibit HIV protease
EP0766674A4 (en) NOVEL HIV PROTEASE INHIBITORS
ES2174921T3 (en) HIV PROTEASE INHIBITORS.
MX9302681A (en) NEW QUINAZOLINS AS REVERSE HIV TRANSCRIPTASE INHIBITORS.
MX9705916A (en) Combination therapy for hiv infection using the hiv protease inhibitor indinavir adn the reverse transcriptase inhibitor 3tc, optionally together with azt, ddi or ddc.
MX9700036A (en) Combination therapy for hiv infection.
AR013758A1 (en) COMBINATION THERAPY FOR THE TREATMENT OF AIDS.
MX9701121A (en) Hiv protease inhibitor combination.
ECSP982741A (en) COMBINED THERAPY FOR THE TREATMENT OF AIDS
ECSP961660A (en) COMBINED THERAPY FOR HIV INFECTION
FI970565A0 (en) HIV proteasinhibitorkombination
DOP2001000263A (en) AZA AND POLIAZA-NAFTALENIL CARBOXAMIDES USEFUL AS INHIBITORS OF HIV INTEGRESS
ECSP900707A (en) AMINO ACID DERIVATIVES